Join BIOCYTOGEN at CABS 2024
We’re excited to announce that we’ll be exhibiting at the CABS 2024 BioPacific Conference in San Francisco, California, on September 7th! This esteemed conference draws over 700 delegates and unites leading basic and clinical scientists from across the globe, all sharing a deep commitment to advancing dermatology. Be part of the conversation as we delve into the newest innovations in lab-based, clinical, and translational research.
What is CABS?
The BioPacific Conference is the annual flagship event of the CABS. Its mission is to unite scientists, executives, and biopharmaceutical professionals from Pacific Rim countries to discuss cutting-edge advancements in life sciences, address the industry’s unprecedented challenges and opportunities, and explore the remarkable developments emerging from the Asia-Pacific region.
Event Overview
Venue:
South San Francisco Conference Center, 255 S Airport Blvd, South San Francisco, CA 94080
Dates: September 7th, 2024
- Conference Day : Saturday 7 September, 2024 8:00am – 6:00pm
Event Schedule
The BioPacific Conference in San Francisco is a dynamic one-day event, showcasing a diverse lineup of speakers and topics. This intensive day will feature thought-provoking discussions and presentations, offering a comprehensive exploration of the latest advancements in the life sciences. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the BioPacific Conference agenda.
September 7th, 2024
- Registration Hours: Vendor Show and Registration
- Exhibit Hall Hours: 8:00am to 6:00pm
- Presentations from 8:30am to 5:30pm
- Topics for Day 1: Biopharma innovations in a global change of AI and big data, Accelerating drug development, data driving discovery to drug, and more
- Reception from 5:30pm to 7:30pm
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the International Cancer Immunotherapy Conference 2024 in Washington, D.C.!
